AU2020219140A1 - Materials and methods for treating a neurodegenerative disease - Google Patents

Materials and methods for treating a neurodegenerative disease Download PDF

Info

Publication number
AU2020219140A1
AU2020219140A1 AU2020219140A AU2020219140A AU2020219140A1 AU 2020219140 A1 AU2020219140 A1 AU 2020219140A1 AU 2020219140 A AU2020219140 A AU 2020219140A AU 2020219140 A AU2020219140 A AU 2020219140A AU 2020219140 A1 AU2020219140 A1 AU 2020219140A1
Authority
AU
Australia
Prior art keywords
fenofibrate
kaempferol
subject
disease
neurodegenerative disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020219140A
Other languages
English (en)
Inventor
Howard J. Federoff
Massimo S. FIANDACA
Mark E. MAPSTONE
Xiaomin SU
Sudhakar Raja SUBRAMANIAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
University of California San Diego UCSD
Original Assignee
Georgetown University
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University, University of California Berkeley, University of California San Diego UCSD filed Critical Georgetown University
Publication of AU2020219140A1 publication Critical patent/AU2020219140A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020219140A 2019-02-05 2020-02-05 Materials and methods for treating a neurodegenerative disease Abandoned AU2020219140A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962801271P 2019-02-05 2019-02-05
US62/801,271 2019-02-05
PCT/US2020/016820 WO2020163493A2 (en) 2019-02-05 2020-02-05 Materials and methods for treating a neurodegenerative disease

Publications (1)

Publication Number Publication Date
AU2020219140A1 true AU2020219140A1 (en) 2022-03-24

Family

ID=71947875

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020219140A Abandoned AU2020219140A1 (en) 2019-02-05 2020-02-05 Materials and methods for treating a neurodegenerative disease

Country Status (9)

Country Link
US (1) US20220401404A1 (https=)
EP (1) EP3930711A4 (https=)
JP (1) JP2022523919A (https=)
CN (1) CN114007607A (https=)
AU (1) AU2020219140A1 (https=)
BR (1) BR112021015466A2 (https=)
CA (1) CA3129050A1 (https=)
MX (1) MX2021009413A (https=)
WO (1) WO2020163493A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021022270A2 (pt) * 2019-05-06 2022-01-11 Univ California Materiais e métodos para tratar degeneração macular relacionada à idade
CN115429788B (zh) * 2022-10-24 2023-11-21 上海中医药大学附属岳阳中西医结合医院 一种治疗脱髓鞘疾病的药物及应用
CN119454686A (zh) * 2024-08-06 2025-02-18 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） 山柰酚或含有山柰酚的组合物在制备治疗和/或缓解多发性硬化症药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1850840A2 (en) 2005-01-13 2007-11-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
WO2009147009A2 (en) * 2008-06-06 2009-12-10 Nicox S.A. Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
US20130252924A1 (en) * 2010-11-11 2013-09-26 Akron Molecules Gmbh Compounds and Methods for Treating Pain
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof
CN105636582A (zh) * 2013-09-18 2016-06-01 乔治城大学 用非诺贝特及其类似物治疗神经退行性疾病
CN109069450A (zh) * 2016-02-05 2018-12-21 法奈克斯公司 神经障碍的新的组合疗法

Also Published As

Publication number Publication date
WO2020163493A2 (en) 2020-08-13
WO2020163493A9 (en) 2020-11-19
US20220401404A1 (en) 2022-12-22
EP3930711A4 (en) 2023-01-11
BR112021015466A2 (pt) 2021-10-19
JP2022523919A (ja) 2022-04-27
CN114007607A (zh) 2022-02-01
EP3930711A2 (en) 2022-01-05
MX2021009413A (es) 2022-01-18
CA3129050A1 (en) 2020-08-13
WO2020163493A3 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
Chung et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation
Lin et al. Omega-3 fatty acids regulate NLRP3 inflammasome activation and prevent behavior deficits after traumatic brain injury
Zhu et al. Neuroprotective effects of Astilbin on MPTP-induced Parkinson's disease mice: Glial reaction, α-synuclein expression and oxidative stress
Patel et al. Cinnamon and its metabolite protect the nigrostriatum in a mouse model of Parkinson’s disease via astrocytic GDNF
EP3046551B1 (en) Treating neurodegenerative disease with fenofibrate and analogs thereof
Li et al. Apelin/APJ system: an emerging therapeutic target for neurological diseases
Jia et al. Erythropoietin attenuates the memory deficits in aging rats by rescuing the oxidative stress and inflammation and promoting BDNF releasing
JP2016517883A (ja) Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
Tutakhail et al. Neuropathology of kynurenine pathway of tryptophan metabolism
Salman et al. Intranasal delivery of mitochondria attenuates brain injury by AMPK and SIRT1/PGC-1α pathways in a murine model of photothrombotic stroke
Gong et al. p47phox deficiency improves cognitive impairment and attenuates tau hyperphosphorylation in mouse models of AD
US20220401404A1 (en) Co-Administration Therapy to Prevent Neurodegeneration and Enhance Neuroprotection
Miyazaki et al. Therapeutic strategy of targeting astrocytes for neuroprotection in Parkinson's disease
CA2985625A1 (en) Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
Kalkman et al. Ceramides May play a central role in the pathogenesis of alzheimer’s disease: a review of evidence and horizons for discovery
JP7850416B2 (ja) 細胞外小胞に含まれるｅｎａｍｐｔの産生および使用
Wu et al. Ginsenoside Rh2 inhibits CBP/p300-mediated FOXO3a acetylation and epilepsy-induced oxidative damage via the FOXO3a–KEAP1–NRF2 pathway
Wang et al. The activation of spliced X-box binding protein 1 by isorhynchophylline therapy improves diabetic encephalopathy
WO2017079161A2 (en) Treatment of neurodegenerative disease with sodium chlorite
Moon et al. Differential effects of pioglitazone in the hippocampal CA1 region following transient forebrain ischemia in low-and high-fat diet-fed gerbils
US20240082184A1 (en) Improved treatment for globoid cell leukodsytrophy or krabbe disease
US20220387393A1 (en) Methods for the treatment of dysmyelinating/demyelinating diseases
Urrutia et al. Iron Neurotoxicity in Parkinson’s Disease
McManus et al. The succinate prodrug NV354 prevents brain lesions and late-stage motor dysfunction in mitochondrial complex I deficiency
US10376484B2 (en) Combination of bezafibrate and of resveratrol or resveratrol derivatives for the treatment and prevention of diseases involving a mitochondrial energy dysfunction

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 05 OCT 2021

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application